Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Bart Barlogie, MD, PhD, Emily Hansen, MS, Sarah Waheed, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Joshua Epstein, DSc

Blood (2013) 122 (21): 3123.

https://doi.org/10.1182/blood.V122.21.3123.3123

Published: 2013

Journal Articles

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Al-Ola Abdallah, MD, Shebli Atrash, MD, Jameel Muzaffar, MD, Nisar Ahmad, MD, Sajjad Haider, MD, Monica Grazziutti, MD, Senu Apewokin, MD, Zainab Shahid, MD, Alejandro Restrepo, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 2925.

https://doi.org/10.1182/blood.V120.21.2925.2925

Published: 2012

Journal Articles

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Sarah Waheed, MD, Monica Grazziutti, MD, Alejandro Restrepo, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bijay Nair, MD, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1962.

https://doi.org/10.1182/blood.V120.21.1962.1962

Published: 2012

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

Journal Articles

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Yazan Alsayed, MD, Sarah Waheed, MD, Jackie Szymonifka, Bijay Nair, MD, MPH, Saad Usmani, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Monica Grazziutti, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1969.

https://doi.org/10.1182/blood.V116.21.1969.1969

Published: 2010

Journal Articles

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, Monica Grazziutti, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 368.

https://doi.org/10.1182/blood.V116.21.368.368

Published: 2010

Journal Articles

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Sarah Waheed, MD, Bijay Nair, MD, MPH, Yazan Alsayed, MD, Monica Grazziutti, Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 4800.

https://doi.org/10.1182/blood.V116.21.4800.4800

Published: 2010

Journal Articles

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Bijay Nair, MD, Monica Grazziutti, PhD, Vanessa Bolejack, PhD, John Crowley, PhD

Blood (2009) 114 (22): 744.

https://doi.org/10.1182/blood.V114.22.744.744

Published: 2009

Journal Articles

Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications.

Somashekar G Krishna, MD, MPH, Zhao Weizhi, Kavya Krishna, MD, Monica Grazziutti, MD, Bart Barlogie, MD, PhD, Elias Anaissie, MD

Blood (2009) 114 (22): 3343.

https://doi.org/10.1182/blood.V114.22.3343.3343

Published: 2009

Journal Articles

Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy

Yue-Jin Wen, Weizhi Zhao, Monica Grazziutti, Wen Ling, Jeanette Lee, Susann M Szmania, Frits van Rhee, Bart Barlogie, Elias J. Anaissie

Blood (2008) 112 (11): 4353.

https://doi.org/10.1182/blood.V112.11.4353.4353

Published: 2008

Journal Articles

Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients

Elias J. Anaissie, MD, Wei-zhi Zhao, Yue-Jin Wen, Monica Grazziutti, Wen Ling, Jeanette Lee, Frits van Rhee, Bart Barlogie

Blood (2008) 112 (11): 667.

https://doi.org/10.1182/blood.V112.11.667.667

Published: 2008

Journal Articles

Immune Reconstruction Inflammatory Syndrome (IRIS) with Invasive Aspergillosis (IA) in Patients (pts) with Hematological Cancer (Hem-Ca): Clinical and Research Implications.

Marisa Miceli, Monica Grazziutti, Gail Woods, Somashekar Krishna, Elias Kiwan, Mazher Rahman, Bart Barlogie, Elias Anaissie, Nayyar Syed

Blood (2006) 108 (11): 5313.

https://doi.org/10.1182/blood.V108.11.5313.5313

Published: 2006

Journal Articles

Validation of Serum Aspergillus Galactomannan Index as a Surrogate Endpoint for Outcome of Invasive Aspergillosis: Clinical and Research Implications.

Gail Woods, Marisa Miceli, Monica Grazziutti, Somashekar Krishna, Nayyar Syed, Elias Kiwan, Mazhar Rahman, Bart Barlogie, Elias Anaissie

Blood (2006) 108 (11): 2861.

https://doi.org/10.1182/blood.V108.11.2861.2861

Published: 2006

NARROW

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications.

Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy

Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients

Immune Reconstruction Inflammatory Syndrome (IRIS) with Invasive Aspergillosis (IA) in Patients (pts) with Hematological Cancer (Hem-Ca): Clinical and Research Implications.

Validation of Serum Aspergillus Galactomannan Index as a Surrogate Endpoint for Outcome of Invasive Aspergillosis: Clinical and Research Implications.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only